James S. Chalfant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James S. Chalfant has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Anne C Hoyt
David Geffen School of Medicine at University of California Los Angeles, Department of Radiological Sciences , Santa Monica, CA , USA
4 shared publicationsDebra M Ikeda
4 shared publicationsBonnie N Joe
3 shared publicationsEric L Rosen
3 shared publicationsHaydee Ojeda-Fournier
3 shared publicationsJohn R Downey
3 shared publications
Latest Publications
- Open Access
- 18 April 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1627-1638
Mammographic classification of interval breast cancers and artificial intelligence performance
Background: European studies suggest that artificial intelligence (AI) can reduce interval breast cancers. Research on interval breast cancer classification and AI’s effectiveness in the United States, however, particularly using digital breast tomosynthesis and annual screening, is limited. We aimed to mammographically classify interval breast cancers and assess AI performance using a 12-month screening interval. Methods: From digital mammography and digital breast tomosynthesis screening mammograms acquired between 2010 and 2019 at a US tertiary-care academic center, we identified interval breast cancers diagnosed less than 12 months after a negative mammogram. At least 3 breast radiologists retrospectively classified interval breast cancers as missed—reading error, minimal signs—actionable, minimal signs—nonactionable, true interval, occult, or missed—technical error. A deep-learning AI tool assigned risk scores ranging from 1 to 10 to the negative index screening mammograms, with scores of 8 or higher considered “flagged.” Statistical analysis evaluated associations among interval breast cancer types and AI exam scores, AI markings, and patient and tumor characteristics. Results: From 184 935 screening mammograms (65% digital mammography, 35% digital breast tomosynthesis), we identified 148 interval breast cancers in 148 women (mean [SD] age = 61 [12] years). Of these, 26% were minimal signs—actionable, 24% were occult, 22% were minimal signs—nonactionable, 17% were missed—reading error, 6% were true interval, and 5% were missed—technical error (P < .001). AI scored 131 mammograms (17 errors excluded); it most frequently flagged exams with missed—reading error (90%), minimal signs—actionable (89%), and minimal signs—nonactionable (72%) (P = .02). AI localized mammographically visible types more accurately (35%-68%) than nonvisible types (0%-50%; P = .02). Conclusion: AI more frequently flagged and accurately localized interval breast cancer types that were mammographically visible at screening (missed or minimal signs) compared with true interval or occult cancers.
- 18 April 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (8) , 1627-1638
Open AccessMammographic classification of interval breast cancers and artificial intelligence performance
Background: European studies suggest that artificial intelligence (AI) can reduce interval breast cancers. Research on interval breast cancer classification and AI’s effectiveness in the United States, however, particularly using digital breast tomosynthesis and annual screening, is limited. We aimed to mammographically classify interval breast cancers and assess AI performance using a 12-month screening interval. Methods: From digital mammography and digital breast tomosynthesis screening mammograms acquired between 2010 and 2019 at a US tertiary-care academic center, we identified interval breast cancers diagnosed less than 12 months after a negative mammogram. At least 3 breast radiologists retrospectively classified interval breast cancers as missed—reading error, minimal signs—actionable, minimal signs—nonactionable, true interval, occult, or missed—technical error. A deep-learning AI tool assigned risk scores ranging from 1 to 10 to the negative index screening mammograms, with scores of 8 or higher considered “flagged.” Statistical analysis evaluated associations among interval breast cancer types and AI exam scores, AI markings, and patient and tumor characteristics. Results: From 184 935 screening mammograms (65% digital mammography, 35% digital breast tomosynthesis), we identified 148 interval breast cancers in 148 women (mean [SD] age = 61 [12] years). Of these, 26% were minimal signs—actionable, 24% were occult, 22% were minimal signs—nonactionable, 17% were missed—reading error, 6% were true interval, and 5% were missed—technical error (P < .001). AI scored 131 mammograms (17 errors excluded); it most frequently flagged exams with missed—reading error (90%), minimal signs—actionable (89%), and minimal signs—nonactionable (72%) (P = .02). AI localized mammographically visible types more accurately (35%-68%) than nonvisible types (0%-50%; P = .02). Conclusion: AI more frequently flagged and accurately localized interval breast cancer types that were mammographically visible at screening (missed or minimal signs) compared with true interval or occult cancers.
- Open Access
- 13 April 2025
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 7 (5) , 513-519
Breast Cancer Screening and Solid Organ Transplantation
Solid organ transplantation volumes in the United States have been steadily increasing over the past decade. Rigorous evaluation of potential transplant recipients must be performed to ensure appropriate allocation of solid organs for transplant. Because active malignancy is a contraindication for most solid organ transplantations, appropriate cancer screening should be included as part of the pretransplant assessment for both potential transplant recipients and donors. This article provides a summary of the current state of solid organ transplant-related breast cancer screening in the United States.
- 13 April 2025
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 7 (5) , 513-519
Open AccessBreast Cancer Screening and Solid Organ Transplantation
Solid organ transplantation volumes in the United States have been steadily increasing over the past decade. Rigorous evaluation of potential transplant recipients must be performed to ensure appropriate allocation of solid organs for transplant. Because active malignancy is a contraindication for most solid organ transplantations, appropriate cancer screening should be included as part of the pretransplant assessment for both potential transplant recipients and donors. This article provides a summary of the current state of solid organ transplant-related breast cancer screening in the United States.
- 14 October 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 7 (1) , 16-26
External Validation of a Commercial Artificial Intelligence Algorithm on a Diverse Population for Detection of False Negative Breast Cancers
Objective: There are limited data on the application of artificial intelligence (AI) on nonenriched, real-world screening mammograms. This work aims to evaluate the ability of AI to detect false negative cancers not detected at the time of screening when reviewed by the radiologist alone. Methods: A commercially available AI algorithm was retrospectively applied to patients undergoing screening full-field digital mammography (FFDM) or digital breast tomosynthesis (DBT) at a single institution from 2010 to 2019. Ground truth was established based on 1-year follow-up data. Descriptive statistics were performed with attention focused on AI detection of false negative cancers within these subsets. Results: A total of 26 694 FFDM and 3183 DBT examinations were analyzed. Artificial intelligence was able to detect 7/13 false negative cancers (54%) in the FFDM cohort and 4/10 (40%) in the DBT cohort on the preceding screening mammogram that was interpreted as negative by the radiologist. Of these, 4 in the FFDM cohort and 4 in the DBT cohort were identified in breast densities of C or greater. False negative cancers detected by AI were predominantly luminal A invasive malignancies (9/11, 82%). Artificial intelligence was able to detect these false negative cancers a median time of 272 days sooner in the FFDM cohort and 248 days sooner in the DBT cohort compared to the radiologist. Conclusion: Artificial intelligence was able to detect cancers at the time of screening that were missed by the radiologist. Prospective studies are needed to evaluate the synergy of AI and the radiologist in real-world settings, especially on DBT examinations.
- 14 October 2024
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 7 (1) , 16-26
External Validation of a Commercial Artificial Intelligence Algorithm on a Diverse Population for Detection of False Negative Breast Cancers
Objective: There are limited data on the application of artificial intelligence (AI) on nonenriched, real-world screening mammograms. This work aims to evaluate the ability of AI to detect false negative cancers not detected at the time of screening when reviewed by the radiologist alone. Methods: A commercially available AI algorithm was retrospectively applied to patients undergoing screening full-field digital mammography (FFDM) or digital breast tomosynthesis (DBT) at a single institution from 2010 to 2019. Ground truth was established based on 1-year follow-up data. Descriptive statistics were performed with attention focused on AI detection of false negative cancers within these subsets. Results: A total of 26 694 FFDM and 3183 DBT examinations were analyzed. Artificial intelligence was able to detect 7/13 false negative cancers (54%) in the FFDM cohort and 4/10 (40%) in the DBT cohort on the preceding screening mammogram that was interpreted as negative by the radiologist. Of these, 4 in the FFDM cohort and 4 in the DBT cohort were identified in breast densities of C or greater. False negative cancers detected by AI were predominantly luminal A invasive malignancies (9/11, 82%). Artificial intelligence was able to detect these false negative cancers a median time of 272 days sooner in the FFDM cohort and 248 days sooner in the DBT cohort compared to the radiologist. Conclusion: Artificial intelligence was able to detect cancers at the time of screening that were missed by the radiologist. Prospective studies are needed to evaluate the synergy of AI and the radiologist in real-world settings, especially on DBT examinations.
- Open Access
- 1 January 2023
- Published by California Digital Library (CDL) in The UCLA Radiological Science Proceedings
- Vol. 3 (4)
Survey on Management of Unilateral Axillary Lymphadenopathy after Recent Ipsilateral COVID-19 Vaccination
Background : In the setting of widespread COVID-19 vaccination and booster administration, there is an increased incidence of axillary lymphadenopathy identified during breast imaging. Purpose : To investigate how breast imaging radiologists manage unilateral axillary lymphadenopathy (UAL) after a recent ipsilateral COVID-19 vaccination. Methods : A 26-question survey was distributed to 12 California breast imaging facilities in June 2022. Results : There were 10 responses to the survey (83% response rate). All respondents considered recent ipsilateral COVID-19 vaccination relevant to the interpretation of UAL. Seven respondents (70%) also considered non-COVID-19 vaccinations relevant. All respondents documented recent COVID-19 vaccinations, but 4 (40%) had no information for other vaccines. Eight respondents (80%) delayed screening after COVID-19 vaccination during initial vaccination efforts, and 3 (30%) still required or suggested delaying screening at the time of the survey. Breast Imaging Reporting and Data System (BI-RADS) categorization for UAL with no abnormal findings in the ipsilateral breast varied by facility and modality. BI-RADS categorization for UAL previously assigned to BI-RADS 0 or associated with suspicious ipsilateral breast findings varied, but practices tended to demonstrate a high level of suspicion unless the UAL showed improvement on follow-up imaging. For unchanged UAL on initial follow-up, 7 (70%) assign BI-RADS 3, and 3 (30%) assign BI-RADS 4. Conclusion : Despite available guidelines, there was no consensus approach to managing UAL after vaccination among academic and community-based breast imaging radiologists in California. Management was more uniform for a subset of patients perceived to be at higher risk for lymph node metastases, with most or all respondents recommending biopsy when there was a suspicious finding in the ipsilateral breast, concurrent ipsilateral breast cancer, or concurrent malignant tumors not in the breast known to metastasize to the axilla.
- 1 January 2023
- Published by California Digital Library (CDL) in The UCLA Radiological Science Proceedings
- Vol. 3 (4)
Open AccessSurvey on Management of Unilateral Axillary Lymphadenopathy after Recent Ipsilateral COVID-19 Vaccination
Background : In the setting of widespread COVID-19 vaccination and booster administration, there is an increased incidence of axillary lymphadenopathy identified during breast imaging. Purpose : To investigate how breast imaging radiologists manage unilateral axillary lymphadenopathy (UAL) after a recent ipsilateral COVID-19 vaccination. Methods : A 26-question survey was distributed to 12 California breast imaging facilities in June 2022. Results : There were 10 responses to the survey (83% response rate). All respondents considered recent ipsilateral COVID-19 vaccination relevant to the interpretation of UAL. Seven respondents (70%) also considered non-COVID-19 vaccinations relevant. All respondents documented recent COVID-19 vaccinations, but 4 (40%) had no information for other vaccines. Eight respondents (80%) delayed screening after COVID-19 vaccination during initial vaccination efforts, and 3 (30%) still required or suggested delaying screening at the time of the survey. Breast Imaging Reporting and Data System (BI-RADS) categorization for UAL with no abnormal findings in the ipsilateral breast varied by facility and modality. BI-RADS categorization for UAL previously assigned to BI-RADS 0 or associated with suspicious ipsilateral breast findings varied, but practices tended to demonstrate a high level of suspicion unless the UAL showed improvement on follow-up imaging. For unchanged UAL on initial follow-up, 7 (70%) assign BI-RADS 3, and 3 (30%) assign BI-RADS 4. Conclusion : Despite available guidelines, there was no consensus approach to managing UAL after vaccination among academic and community-based breast imaging radiologists in California. Management was more uniform for a subset of patients perceived to be at higher risk for lymph node metastases, with most or all respondents recommending biopsy when there was a suspicious finding in the ipsilateral breast, concurrent ipsilateral breast cancer, or concurrent malignant tumors not in the breast known to metastasize to the axilla.
- 17 June 2022
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 4 (4) , 371-377
Breast Density Legislation Impact on Breast Cancer Screening and Risk Assessment
To evaluate breast density notification legislation (BDNL) on breast imaging practice patterns, risk assessment, and supplemental screening. A 20-question anonymous web-based survey was administered to practicing Society of Breast Imaging radiologists in the U.S. between February and April 2021 regarding breast cancer risk assessment, supplemental screening, and density measurements. Results were compared between facilities with and without BDNL using the two-sided Fisher’s exact test. One hundred and ninety-seven radiologists from 41 U.S. states, with (187/197, 95%) or without (10/197, 5%) BDNL, responded. Fifty-seven percent (113/197) performed breast cancer risk assessment, and 93% (183/197) offered supplemental screening for women with dense breasts. Between facilities with or without BDNL, there was no significant difference in whether risk assessment was (P = 0.19) or was not performed (P = 0.20). There was no significant difference in supplemental screening types (P > 0.05) between BDNL and non-BDNL facilities. Thirty-five percent (69/197) of facilities offered no supplemental screening studies, and 25% (49/197) had no future plans to offer supplemental screening. A statistically significant greater proportion of non-BDNL facilities offered no supplemental screening (P < 0.03) and had no plans to offer supplemental screening compared to BDNL facilities (P < 0.02). Facilities in BDNL states often offer supplemental screening compared to facilities in non-BDNL states. Compared to BDNL facilities, a statistically significant proportion of non-BDNL facilities had no supplemental screening nor plans for implementation. Our data suggest that upcoming federal BDNL will impact how supplemental screening is addressed in currently non-BDNL states.
- 17 June 2022
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 4 (4) , 371-377
Breast Density Legislation Impact on Breast Cancer Screening and Risk Assessment
To evaluate breast density notification legislation (BDNL) on breast imaging practice patterns, risk assessment, and supplemental screening. A 20-question anonymous web-based survey was administered to practicing Society of Breast Imaging radiologists in the U.S. between February and April 2021 regarding breast cancer risk assessment, supplemental screening, and density measurements. Results were compared between facilities with and without BDNL using the two-sided Fisher’s exact test. One hundred and ninety-seven radiologists from 41 U.S. states, with (187/197, 95%) or without (10/197, 5%) BDNL, responded. Fifty-seven percent (113/197) performed breast cancer risk assessment, and 93% (183/197) offered supplemental screening for women with dense breasts. Between facilities with or without BDNL, there was no significant difference in whether risk assessment was (P = 0.19) or was not performed (P = 0.20). There was no significant difference in supplemental screening types (P > 0.05) between BDNL and non-BDNL facilities. Thirty-five percent (69/197) of facilities offered no supplemental screening studies, and 25% (49/197) had no future plans to offer supplemental screening. A statistically significant greater proportion of non-BDNL facilities offered no supplemental screening (P < 0.03) and had no plans to offer supplemental screening compared to BDNL facilities (P < 0.02). Facilities in BDNL states often offer supplemental screening compared to facilities in non-BDNL states. Compared to BDNL facilities, a statistically significant proportion of non-BDNL facilities had no supplemental screening nor plans for implementation. Our data suggest that upcoming federal BDNL will impact how supplemental screening is addressed in currently non-BDNL states.
- 6 June 2022
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 4 (4) , 357-370
Breast Density: Current Knowledge, Assessment Methods, and Clinical Implications
Breast density is an accepted independent risk factor for the future development of breast cancer, and greater breast density has the potential to mask malignancies on mammography, thus lowering the sensitivity of screening mammography. The risk associated with dense breast tissue has been shown to be modifiable with changes in breast density. Numerous studies have sought to identify factors that influence breast density, including age, genetic, racial/ethnic, prepubertal, adolescent, lifestyle, environmental, hormonal, and reproductive history factors. Qualitative, semiquantitative, and quantitative methods of breast density assessment have been developed, but to date there is no consensus assessment method or reference standard for breast density. Breast density has been incorporated into breast cancer risk models, and there is growing consciousness of the clinical implications of dense breast tissue in both the medical community and public arena. Efforts to improve breast cancer screening sensitivity for women with dense breasts have led to increased attention to supplemental screening methods in recent years, prompting the American College of Radiology to publish Appropriateness Criteria for supplemental screening based on breast density.
- 6 June 2022
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 4 (4) , 357-370
Breast Density: Current Knowledge, Assessment Methods, and Clinical Implications
Breast density is an accepted independent risk factor for the future development of breast cancer, and greater breast density has the potential to mask malignancies on mammography, thus lowering the sensitivity of screening mammography. The risk associated with dense breast tissue has been shown to be modifiable with changes in breast density. Numerous studies have sought to identify factors that influence breast density, including age, genetic, racial/ethnic, prepubertal, adolescent, lifestyle, environmental, hormonal, and reproductive history factors. Qualitative, semiquantitative, and quantitative methods of breast density assessment have been developed, but to date there is no consensus assessment method or reference standard for breast density. Breast density has been incorporated into breast cancer risk models, and there is growing consciousness of the clinical implications of dense breast tissue in both the medical community and public arena. Efforts to improve breast cancer screening sensitivity for women with dense breasts have led to increased attention to supplemental screening methods in recent years, prompting the American College of Radiology to publish Appropriateness Criteria for supplemental screening based on breast density.
- 1 January 2022
- Published by Springer Nature
- p. 1-35
Regulations and Standards of Care
- Open Access
- 27 September 2021
- Published by Springer Nature in Current Radiology Reports
- Vol. 9 (10) , 1-10
Background Parenchymal Enhancement on Breast MRI: Assessment and Clinical Implications
Purpose of Review: To present recent literature regarding the assessment and clinical implications of background parenchymal enhancement on breast MRI.Recent Findings: The qualitative assessment of BPE remains variable within the literature, as well as in clinical practice. Several different quantitative approaches have been investigated in recent years, most commonly region of interest-based and segmentation-based assessments. However, quantitative assessment has not become standard in clinical practice to date. Numerous studies have demonstrated a clear association between higher BPE and future breast cancer risk. While higher BPE does not appear to significantly impact cancer detection, it may result in a higher abnormal interpretation rate. BPE is also likely a marker of pathologic complete response after neoadjuvant chemotherapy, with decreases in BPE during and after neoadjuvant chemotherapy correlated with pCR. In contrast, pre-treatment BPE does not appear to be predictive of pCR. The association between BPE and prognosis is less clear, with heterogeneous results in the literature.Summary: Assessment of BPE continues to evolve, with heterogeneity in approaches to both qualitative and quantitative assessment. The level of BPE has important clinical implications, with associations with future breast cancer risk and treatment response. BPE may also be an imaging marker of prognosis, but future research is needed on this topic.
- 27 September 2021
- Published by Springer Nature in Current Radiology Reports
- Vol. 9 (10) , 1-10
Open AccessBackground Parenchymal Enhancement on Breast MRI: Assessment and Clinical Implications
Purpose of Review: To present recent literature regarding the assessment and clinical implications of background parenchymal enhancement on breast MRI.Recent Findings: The qualitative assessment of BPE remains variable within the literature, as well as in clinical practice. Several different quantitative approaches have been investigated in recent years, most commonly region of interest-based and segmentation-based assessments. However, quantitative assessment has not become standard in clinical practice to date. Numerous studies have demonstrated a clear association between higher BPE and future breast cancer risk. While higher BPE does not appear to significantly impact cancer detection, it may result in a higher abnormal interpretation rate. BPE is also likely a marker of pathologic complete response after neoadjuvant chemotherapy, with decreases in BPE during and after neoadjuvant chemotherapy correlated with pCR. In contrast, pre-treatment BPE does not appear to be predictive of pCR. The association between BPE and prognosis is less clear, with heterogeneous results in the literature.Summary: Assessment of BPE continues to evolve, with heterogeneity in approaches to both qualitative and quantitative assessment. The level of BPE has important clinical implications, with associations with future breast cancer risk and treatment response. BPE may also be an imaging marker of prognosis, but future research is needed on this topic.
- Open Access
- 9 March 2021
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 3 (3) , 343-353
Adaptations of Breast Imaging Centers to the COVID-19 Pandemic: A Survey of California and Texas
To determine the early impact of the COVID-19 pandemic on breast imaging centers in California and Texas and compare regional differences. An 11-item survey was emailed to American College of Radiology accredited breast imaging facilities in California and Texas in August 2020. A question subset addressed March-April government restrictions on elective services (“during the shutdown” and “after reopening”). Comparisons were made between states with chi-square and Fisher’s tests, and time frames with McNemar’s and paired t-tests. There were 54 respondents (54/240, 23%, 26 California, 28 Texas). Imaging volumes fell during the shutdown and remained below pre-pandemic levels after reopening, with reduction in screening greatest (ultrasound 12% of baseline, mammography 13%, MRI 23%), followed by diagnostic MRI (43%), procedures (44%), and diagnostics (45%). California reported higher volumes during the shutdown (procedures, MRI) and after reopening (diagnostics, procedures, MRI) versus Texas (P = 0.001 - 0.02). Most screened patients (52/54, 96% symptoms and 42/54, 78% temperatures), and 100% (53/53) modified check-in and check-out. Reading rooms or physician work were altered for social distancing (31/54, 57%). Physician mask (45/48, 94%), gown (15/48, 31%), eye wear (22/48, 46%), and face shield (22/48, 46%) use during procedures increased after reopening versus pre-pandemic (P < 0.001 - 0.03). Physician (47/54, 87%) and staff (45/53, 85%) financial impacts were common, but none reported terminations. Breast imaging volumes during the early pandemic fell more severely in Texas than in California. Safety measures and financial impacts on physicians and staff were similar in both states.
- 9 March 2021
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 3 (3) , 343-353
Open AccessAdaptations of Breast Imaging Centers to the COVID-19 Pandemic: A Survey of California and Texas
To determine the early impact of the COVID-19 pandemic on breast imaging centers in California and Texas and compare regional differences. An 11-item survey was emailed to American College of Radiology accredited breast imaging facilities in California and Texas in August 2020. A question subset addressed March-April government restrictions on elective services (“during the shutdown” and “after reopening”). Comparisons were made between states with chi-square and Fisher’s tests, and time frames with McNemar’s and paired t-tests. There were 54 respondents (54/240, 23%, 26 California, 28 Texas). Imaging volumes fell during the shutdown and remained below pre-pandemic levels after reopening, with reduction in screening greatest (ultrasound 12% of baseline, mammography 13%, MRI 23%), followed by diagnostic MRI (43%), procedures (44%), and diagnostics (45%). California reported higher volumes during the shutdown (procedures, MRI) and after reopening (diagnostics, procedures, MRI) versus Texas (P = 0.001 - 0.02). Most screened patients (52/54, 96% symptoms and 42/54, 78% temperatures), and 100% (53/53) modified check-in and check-out. Reading rooms or physician work were altered for social distancing (31/54, 57%). Physician mask (45/48, 94%), gown (15/48, 31%), eye wear (22/48, 46%), and face shield (22/48, 46%) use during procedures increased after reopening versus pre-pandemic (P < 0.001 - 0.03). Physician (47/54, 87%) and staff (45/53, 85%) financial impacts were common, but none reported terminations. Breast imaging volumes during the early pandemic fell more severely in Texas than in California. Safety measures and financial impacts on physicians and staff were similar in both states.
- 9 March 2021
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 3 (3) , 354-362
Impact of the COVID-19 Pandemic on Breast Imaging Education
To determine the impact of the COVID-19 pandemic on breast imaging education. A 22-item survey addressing four themes during the early pandemic (time on service, structured education, clinical training, future plans) was emailed to Society of Breast Imaging members and members-in-training in July 2020. Responses were compared using McNemar’s and Mann-Whitney U tests; a general linear model was used for multivariate analysis. Of 136 responses (136/2824, 4.8%), 96 U.S. responses from radiologists with trainees, residents, and fellows were included. Clinical exposure declined during the early pandemic, with almost no medical students on service (66/67, 99%) and fewer clinical days for residents (78/89, 88%) and fellows (48/68, 71%). Conferences shifted to remote live format (57/78, 73%), with some canceled (15/78, 19%). Compared to pre-pandemic, resident diagnostic (75/78, 96% vs 26/78, 33%) (P < 0.001) and procedural (73/78, 94% vs 21/78, 27%) (P < 0.001) participation fell, as did fellow diagnostic (60/61, 98% vs 47/61, 77%) (P = 0.001) and procedural (60/61, 98% vs 43/61, 70%) (P < 0.001) participation. Most thought that the pandemic negatively influenced resident and fellow screening (64/77, 83% and 43/60, 72%, respectively), diagnostic (66/77, 86% and 37/60, 62%), and procedural (71/77, 92% and 37/61, 61%) education. However, a majority thought that decreased time on service (36/67, 54%) and patient contact (46/79, 58%) would not change residents’ pursuit of a breast imaging fellowship. The pandemic has had a largely negative impact on breast imaging education, with reduction in exposure to all aspects of breast imaging. However, this may not affect career decisions.
- 9 March 2021
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 3 (3) , 354-362
Impact of the COVID-19 Pandemic on Breast Imaging Education
To determine the impact of the COVID-19 pandemic on breast imaging education. A 22-item survey addressing four themes during the early pandemic (time on service, structured education, clinical training, future plans) was emailed to Society of Breast Imaging members and members-in-training in July 2020. Responses were compared using McNemar’s and Mann-Whitney U tests; a general linear model was used for multivariate analysis. Of 136 responses (136/2824, 4.8%), 96 U.S. responses from radiologists with trainees, residents, and fellows were included. Clinical exposure declined during the early pandemic, with almost no medical students on service (66/67, 99%) and fewer clinical days for residents (78/89, 88%) and fellows (48/68, 71%). Conferences shifted to remote live format (57/78, 73%), with some canceled (15/78, 19%). Compared to pre-pandemic, resident diagnostic (75/78, 96% vs 26/78, 33%) (P < 0.001) and procedural (73/78, 94% vs 21/78, 27%) (P < 0.001) participation fell, as did fellow diagnostic (60/61, 98% vs 47/61, 77%) (P = 0.001) and procedural (60/61, 98% vs 43/61, 70%) (P < 0.001) participation. Most thought that the pandemic negatively influenced resident and fellow screening (64/77, 83% and 43/60, 72%, respectively), diagnostic (66/77, 86% and 37/60, 62%), and procedural (71/77, 92% and 37/61, 61%) education. However, a majority thought that decreased time on service (36/67, 54%) and patient contact (46/79, 58%) would not change residents’ pursuit of a breast imaging fellowship. The pandemic has had a largely negative impact on breast imaging education, with reduction in exposure to all aspects of breast imaging. However, this may not affect career decisions.